TritonPoint Partners’s Immix Biopharma IMMX Stock Holding History

TritonPoint Partners’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$253K	Hold	24,526	–	–	0.02%	314
2026 Q1	$223K	Hold	24,526	–	–	0.08%	187
2025 Q4	$128K	Buy	+24,526	New	+$101K	0.07%	150

Other funds holding IMMX

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TritonPoint Partners's IMMX Position: Q2 2026 in Review

TritonPoint Partners held its Immix Biopharma (IMMX) position steady in Q2 2026 at 24,526 shares worth $253K. The position accounts for 0.02% of the portfolio, ranked #314.

TritonPoint Partners first reported a position in IMMX in Q4 2025 and has held it in 3 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

TritonPoint Partners held 24,526 shares of Immix Biopharma worth $253K as of Q2 2026.
TritonPoint Partners left its Immix Biopharma share count unchanged in Q2 2026.
Immix Biopharma made up 0.02% of TritonPoint Partners's portfolio in Q2 2026, its #314 holding.
TritonPoint Partners first reported a position in Immix Biopharma in Q4 2025 and has held it in 3 quarters since.
109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on TritonPoint Partners's 13F filing for Q2 2026, filed 13 Aug 2026.